Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()

類似資料

• Tumor Dynamics in Response to Antiangiogenic Therapy with Oral Metronomic Topotecan and Pazopanib in Neuroblastoma Xenografts
  著者:: Kumar, Sushil, 等
  出版事項: (2013)
• Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models
  著者:: Sun, Jessica D, 等
  出版事項: (2015)
• Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
  著者:: Sun, Jessica D, 等
  出版事項: (2015)
• In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model
  著者:: Zhang, Libo, 等
  出版事項: (2009)
• Tissue Microenvironment Modulates CXCR4 Expression and Tumor Metastasis in Neuroblastoma
  著者:: Zhang, Libo, 等
  出版事項: (2007)